Compound A Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
vs
Compound B Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
Molecular weight
1419.53 g/mol
4963.44 g/mol
Half-life
~4 hours (stable in gastric juice — unique among peptides)
~14 days
Admin routes
subcutaneous intramuscular oral topical
subcutaneous intramuscular topical
Research areas
Tendon/ligament repair Gut healing (IBD, ulcers, leaky gut) Muscle injury recovery Neuroprotection Bone fracture healing Wound healing Organ protection (liver, pancreas, heart)
Tissue repair Cardiac repair Wound healing Hair regrowth Anti-inflammation Renal protection Corneal repair
Typical dosing
250–500 mcg · 1-2x daily · 4-12 weeks
2000–5000 mcg · 2x weekly · 4-8 weeks loading, 4 weeks maintenance
FDA status
Not FDA-approved and NOT compoundable as of June 2026 (per regulatory-status-refresh-2026-06): removed from the Category 2 do-not-compound list in April 2026 (nomination withdrawn, effective 2026-04-23) — this is a procedural step, not approval, and BPC-157 is NOT Category 1. PCAC review scheduled Jul 23, 2026. Also WADA-prohibited (S0).
Not FDA-approved. FDA Category 2 (under evaluation for compounding)
WADA status
Prohibited (S0 category — non-approved substances, effective January 2022)
Prohibited (S0 — non-approved substances, effective 2011)
